Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 022567
Company: ABBVIE
Company: ABBVIE
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
VIIBRYD | VILAZODONE HYDROCHLORIDE | 10MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
VIIBRYD | VILAZODONE HYDROCHLORIDE | 20MG | TABLET;ORAL | Prescription | AB | Yes | No |
VIIBRYD | VILAZODONE HYDROCHLORIDE | 40MG | TABLET;ORAL | Prescription | AB | Yes | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
01/21/2011 | ORIG-1 | Approval | Type 1 - New Molecular Entity | STANDARD |
Label (PDF)
Letter (PDF) Review Summary Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022567s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000SumR.pdf |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
04/19/2024 | SUPPL-25 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022567s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/020822Orig1s055; 021365Orig1s041; 021323Orig1s058; 022567Orig1s025; 204168Orig1s012ltr.pdf | |
08/18/2023 | SUPPL-24 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022567s024lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204168Orig1s011,022567Orig1s024ltr.pdf | |
09/20/2021 | SUPPL-22 | Labeling-Package Insert, Labeling-Medication Guide |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/020822Orig1s052, 021365Orig1s038, 021323Orig1s053, 022567Orig1s022, 204168Orig1s007ltr.pdf | |
01/31/2020 | SUPPL-21 | Efficacy-Labeling Change With Clinical Data |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/022567Orig1s021ltr.pdf | |
01/04/2017 | SUPPL-20 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022567s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/020822Orig1s047,021323Orig1s047,021365Orig1s035,022567Orig1s020ltr.pdf | |
09/06/2016 | SUPPL-19 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022567s019lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/022567Orig1s019ltr.pdf | |
12/16/2015 | SUPPL-16 | Manufacturing (CMC) |
Label is not available on this site. |
||
06/11/2015 | SUPPL-15 | Manufacturing (CMC) |
Label is not available on this site. |
||
07/16/2014 | SUPPL-13 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022567s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022567Orig1s013ltr.pdf | |
03/16/2015 | SUPPL-12 | Efficacy-New Dosing Regimen |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022567s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022567Orig1s012ltr.pdf | |
04/07/2014 | SUPPL-11 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022567s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022567Orig1s011ltr.pdf | |
04/17/2014 | SUPPL-10 | Manufacturing (CMC) |
Label is not available on this site. |
||
12/17/2013 | SUPPL-9 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022567s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022567Orig1s009ltr.pdf | |
06/08/2013 | SUPPL-8 | Manufacturing (CMC) |
Label is not available on this site. |
||
01/10/2013 | SUPPL-7 | Manufacturing (CMC) |
Label is not available on this site. |
||
12/14/2012 | SUPPL-6 | Manufacturing (CMC) |
Label is not available on this site. |
||
12/21/2012 | SUPPL-5 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022567s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022567Orig1s005ltr.pdf | |
06/29/2011 | SUPPL-2 | REMS-Modified, REMS-Assessment |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022567s002ltr.pdf |
09/21/2011 | SUPPL-1 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/022567s001ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
04/19/2024 | SUPPL-25 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022567s025lbl.pdf | |
08/18/2023 | SUPPL-24 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022567s024lbl.pdf | |
09/20/2021 | SUPPL-22 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf | |
09/20/2021 | SUPPL-22 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022567s022lbl.pdf | |
01/31/2020 | SUPPL-21 | Efficacy-Labeling Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022567s021lbl.pdf | |
01/04/2017 | SUPPL-20 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022567s020lbl.pdf | |
09/06/2016 | SUPPL-19 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022567s019lbl.pdf | |
03/16/2015 | SUPPL-12 | Efficacy-New Dosing Regimen | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022567s012lbl.pdf | |
07/16/2014 | SUPPL-13 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022567s013lbl.pdf | |
04/07/2014 | SUPPL-11 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022567s011lbl.pdf | |
12/17/2013 | SUPPL-9 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022567s009lbl.pdf | |
12/21/2012 | SUPPL-5 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022567s005lbl.pdf | |
09/21/2011 | SUPPL-1 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s001lbl.pdf | |
01/21/2011 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s000lbl.pdf |
VIIBRYD
TABLET;ORAL; 10MG
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
VIIBRYD | VILAZODONE HYDROCHLORIDE | 10MG | TABLET;ORAL | Prescription | Yes | AB | 022567 | ABBVIE |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 10MG | TABLET;ORAL | Prescription | No | AB | 208209 | ACCORD HLTHCARE |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 10MG | TABLET;ORAL | Prescription | No | AB | 208202 | ALEMBIC |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 10MG | TABLET;ORAL | Prescription | No | AB | 208228 | APOTEX |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 10MG | TABLET;ORAL | Prescription | No | AB | 208200 | INVAGEN PHARMS |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 10MG | TABLET;ORAL | Prescription | No | AB | 208212 | TEVA PHARMS USA |
TABLET;ORAL; 20MG
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
VIIBRYD | VILAZODONE HYDROCHLORIDE | 20MG | TABLET;ORAL | Prescription | Yes | AB | 022567 | ABBVIE |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 20MG | TABLET;ORAL | Prescription | No | AB | 208209 | ACCORD HLTHCARE |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 20MG | TABLET;ORAL | Prescription | No | AB | 208202 | ALEMBIC |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 20MG | TABLET;ORAL | Prescription | No | AB | 208228 | APOTEX |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 20MG | TABLET;ORAL | Prescription | No | AB | 208200 | INVAGEN PHARMS |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 20MG | TABLET;ORAL | Prescription | No | AB | 208212 | TEVA PHARMS USA |
TABLET;ORAL; 40MG
TE Code = AB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
---|---|---|---|---|---|---|---|---|
VIIBRYD | VILAZODONE HYDROCHLORIDE | 40MG | TABLET;ORAL | Prescription | Yes | AB | 022567 | ABBVIE |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 40MG | TABLET;ORAL | Prescription | No | AB | 208209 | ACCORD HLTHCARE |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 40MG | TABLET;ORAL | Prescription | No | AB | 208202 | ALEMBIC |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 40MG | TABLET;ORAL | Prescription | No | AB | 208228 | APOTEX |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 40MG | TABLET;ORAL | Prescription | No | AB | 208200 | INVAGEN PHARMS |
VILAZODONE HYDROCHLORIDE | VILAZODONE HYDROCHLORIDE | 40MG | TABLET;ORAL | Prescription | No | AB | 208212 | TEVA PHARMS USA |